SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

UPDATE

Shire takes over SCM Pharma, after manufacturing license is revoked

14-Aug-2014 - Shire has entered SCM Pharma into administration and acquired its assets after the CDMO lost its cGMP license at a UK sterile plant.

Injectables outsourcing growing despite pharma M&A, says AMRI

06-Aug-2014 - Big Pharma is still reliant on CMOs despite talk of returning in-house, says AMRI, which has launched into the top ten manufacturers in the US injectables sector following its recent...

Icon's robust Q2 driven by strategic partners and new clients

05-Aug-2014 - Icon has picked up new clients and expanded existing contracts in a robust Q2, but the CRO says it has seen no overall shift in its client concentration with strategic partners...

Global trials growth driving CRO consolidation, says M&A report

29-Jul-2014 - Increased emphasis on global clinical trials is promoting consolidation of contract research organisations (CROs), according to an industry report by M&A services firm 11T Partners.

Strategic partnerships driving consolidation of CDMO industry, says report

24-Jul-2014 - Growth of Pharma strategic partnerships with contract development and manufacturing organisations (CDMOs) is driving consolidation, according to an industry report.

UPDATE

Sterile injectables M&A could indicate return to in-house production

22-Jul-2014 - Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.

Big Pharma's 'intellectual arrogance' stunts CMO partnerships, says GPCM Chair

22-Jul-2014 - Efficient relationships with contract manufacturers are being held back by Big Pharma’s ‘intellectual arrogance’ and ill-defined operational teams, according to an ex-Director at GlaxoSmithKline.

Chiltern taps oncology expertise with Ockham acquisition

16-Jul-2014 - UK-based CRO Chiltern has agreed to acquire Ockham, a North Carolina-based full-service CRO, and the combined company will now compete with mid-sized CROs. Financial terms of the acquisition were not...

CROs see high jobs growth as bio industry remains relatively flat, report finds

15-Jul-2014 - While the overall bioscience industry has seen 7.4% jobs growth between 2001 and 2012, the sector encompassing CROs and other research, testing and medical labs has grown by more than...

Clinical Cymru: Simbec Research buys Orion Clinical Services for £12.5m

24-Jun-2014 - Simbec Research has bought Orion Clinical Services in the latest deal backed by the Welsh Government’s £100m life sciences investment fund.

Dispatches from the GPCM Conference, London, UK

For big pharma, ten is the magic number of CMOs says ex-GSK Director

18-Jun-2014 - Big pharma is moving towards strategic partnerships with CMOs, according to speakers at the Global Pharmaceutical Contract Manufacturing (GPCM) Conference, with the ideal number of partners being ten.

Business as usual for CROs as megamerger optimism subsides

11-Jun-2014 - When it comes to pharma acquisitions size does matter, according to analyst Ross Muken who says the momentary lapse in megamergers means business as usual for CROs.

Hikma eyes Ben Venue's assets as part of $300m Bedford Labs acquistion

29-May-2014 - Hikma Pharmaceuticals says it is evaluating Ben Venue’s manufacturing facility as an option in its $300m (€220m) acquisition of Bedford Laboratories.

Exclusive Interview

Lilly focuses in-house as manufacturing becomes more complex

27-May-2014 - Eli Lilly is maintaining greater in-house control as manufacturing processes become more complex, whilst MSD is leveraging external over-capacity to fulfil its needs, the firms told Outsourcing-Pharma.com during a recent...

Huntingdon buys Harlan to form 3rd largest preclinical CRO

07-May-2014 - Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.

Quintiles, Covance upbeat on further pharma consolidation

06-May-2014 - Quintiles and Covance have re-iterated previous CROs’ upbeat stances on the prospect for further pharma M&A as they both reported revenue growth for the quarter.

Icon and Parexel: Pfizer-AZ merger will bring more business for CROs

05-May-2014 - A mega-merger between Pfizer and AstraZeneca would bring increased business to CROs say Icon and Parexel, if past experiences are to go by.

Hot topic

PE's unclear role in CRO industry leaves sponsors 'uncomfortable,' says expert

28-Apr-2014 - The relationship between private equity (PE) management and that of its CRO is “pivotal,” according to the Chairman of one pharma group, as PE’s undefined objectives and exit strategies are...

Biogen Idec selects Quintiles in 5-year strategic partnership

24-Apr-2014 - Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross...

CROs to profit from large slice of $91bn biotech pie, say analysts

10-Apr-2014 - Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst...

Pernix leaves CMO business behind, sells off last manufacturing facility in Texas

03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.

Completed Galapagos deal to boost 2014 sales by $70m for Charles River

02-Apr-2014 - Argenta and BioFocus will add approximately $70m (€51m) to Charles River Laboratories’ 2014 revenues, the firm and an analyst say.

Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.

Evotec buys academic asset management specialist

24-Mar-2014 - Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.

DISPATCHES FROM INTERPHEX

Patheon and DSM crossover limited, more growth targeted says DPx

20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.